Urien S, Brée F, Breillout F, Bastian G, Krikorian A, Tillement J P
Laboratoire de Pharmacologie, Faculté de Médecine, Créteil, France.
Cancer Chemother Pharmacol. 1993;32(3):231-4. doi: 10.1007/BF00685841.
Using [3H]-vinorelbine, we demonstrated the presence of saturable and time-dependent high-affinity binding sites on human platelets and lymphocytes. The dissociation constant and binding-site values observed were 200 +/- 38 nM, 20.0 +/- 2.2 amol/platelet, and 155 +/- 20 amol/lymphocyte, respectively. Among other blood components, saturable low-affinity binding of vinorelbine to alpha 1-acid glycoprotein, serum albumin, and lipoproteins was observed. The binding to erythocytes was nonsaturable. Given the relative concentrations of these carriers, vinorelbine mainly distributes in the platelet compartment in blood (> 70%), and the amount of free vinorelbine in plasma relative to the total amount in blood is < 2%. It is suggested that because of the preferential retention of vinorelbine by platelets, variations in the platelet count are very likely to produce changes in the free blood fraction of vinorelbine.
使用[³H] - 长春瑞滨,我们证明了人血小板和淋巴细胞上存在可饱和且时间依赖性的高亲和力结合位点。观察到的解离常数和结合位点值分别为200±38 nM、20.0±2.2 amol/血小板和155±20 amol/淋巴细胞。在其他血液成分中,观察到长春瑞滨与α1 - 酸性糖蛋白、血清白蛋白和脂蛋白存在可饱和的低亲和力结合。与红细胞的结合是非饱和的。鉴于这些载体的相对浓度,长春瑞滨主要分布在血液中的血小板部分(>70%),血浆中游离长春瑞滨相对于血液总量的比例<2%。提示由于血小板对长春瑞滨的优先保留,血小板计数的变化很可能会导致长春瑞滨游离血药分数的改变。